ASCO 2022 Conference Coverage


 

ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy

64 views
June 10, 2022
Comments 0
Login to view comments. Click here to Login